Trial reportTechniques in coloproctology2014
Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.
Trial report in Techniques in coloproctology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy.World journal of surgical oncology · 2021Pooled it
- Safety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study.International journal of surgery (London, England) · 2025Trial
- Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen.Radiation oncology (London, England) · 2016Trial
- Clinical utility and future directions of FDG-PET in rectal cancer management.Annals of nuclear medicine · 2026Review
- The Ongoing Development of Watch and Wait.Clinics in colon and rectal surgery · 2025Review
- Outcomes of Postchemoradiotherapy Watch-and-Wait Strategy in Patients With Rectal Cancer: A 20-Year, Single-Center Study.Journal of surgical oncology · 2025Article
- Predictive value of flexible proctosigmoidoscopy and laboratory findings for complete clinical responses after neoadjuvant chemoradiotherapy in patients with locally advanced primary rectal cancer: a retrospective cohort study.International journal of colorectal disease · 2024Article
- A management of patients achieving clinical complete response after neoadjuvant therapy and perspectives: on locally advanced rectal cancer.Frontiers in oncology · 2024Review
- Sense and non-sense of imaging in the era of organ preservation for rectal cancer.The British journal of radiology · 2023Review
- Article
- Watch and Wait Approach for Rectal Cancer.Journal of clinical medicine · 2023Review
- Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer.International journal of colorectal disease · 2022Article
- Role of 18F-PET-CT to predict pathological response after neoadjuvant treatment of rectal cancer.Discover oncology · 2021Article
- Nonoperative Management for T2 Low Rectal Cancer: A Western Approach.Clinics in colon and rectal surgery · 2020Review
- The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.International journal of molecular sciences · 2020Review
- Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.The Journal of surgical research · 2019Article
- Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.Annals of coloproctology · 2019Review
- Development and validation of an MRI-based model to predict response to chemoradiotherapy for rectal cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2018Article
- The good, the bad and the ugly: rectal cancers in the twenty-first century.Techniques in coloproctology · 2017Article
- Management of adenomas within the area of rectal cancer that develop complete pathological response.International journal of colorectal disease · 2015Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular imaging using positron emission tomography/computerized tomography (PET/CT) may add relevant incremental diagnostic information to standard structural cross-sectional imaging. Such information may allow identification of patients with rectal cancer that are more likely to develop complete tumor regression after neoadjuvant chemoradiation therapy (CRT). The objective of this report was to identify PET/CT features that are associated with a complete response after CRT.
methods99 cT2-4N0-2M0 distal rectal cancer patients (≤7 cm from anal verge) were included in this prospective single center trial (NCT 00254683). Patients underwent baseline PET/CT followed by 54 Gy and 5-fluorouracil-based neoadjuvant CRT. After completion of therapy, patients underwent 6- and 12-week PET/CT. Clinical assessment of tumor response was performed at 12 weeks and was blinded to radiological information. Patients were treated according to clinical assessment.
resultsThere were seven patients with a complete pathological response (pCR) and 16 with a complete clinical response (cCR) (23 complete responders). Comparison of pCR exclusively and non-pCR revealed that only baseline primary tumor standard uptake value (SUV) was a significant predictor of response. Comparison of complete responders (pCR or cCR) and non-complete responders showed that depth of rectal wall uptake at baseline PET/CT (p = 0.002) and variation between baseline and 12-week maximum standard uptake value (SUVmax) of primary tumor (p = 0.001) were independent predictors for complete response at multivariate analysis. A decrease >67 % between baseline and 6-week or 76 % between baseline and 12-week SUVmax were associated with complete response (pCR or cCR; p = 0.02 and p < 0.001, respectively).
conclusionsPositron emission tomography/computerized tomography at baseline, 6 and 12 weeks, may provide information regarding patients with a higher likelihood of developing complete tumor regression following neoadjuvant CRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.